Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa

Little is known about the time to sputum culture conversion in MDR-TB patients co-infected with HIV, although such patients have, historically, had poor outcomes. We describe culture conversion rates among MDR-TB patients with and without HIV-co-infection in a TB-endemic, high-HIV prevalent, resourc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one Jg. 6; H. 1; S. e15841
Hauptverfasser:	Brust, James C. M., Lygizos, Melissa, Chaiyachati, Krisda, Scott, Michelle, van der Merwe, Theo L., Moll, Anthony P., Li, Xuan, Loveday, Marian, Bamber, Sheila A., Lalloo, Umesh G., Friedland, Gerald H., Shah, N. Sarita, Gandhi, Neel R.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Public Library of Science 06.01.2011 Public Library of Science (PLoS)
Schlagworte:	Adult Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antitubercular Agents - therapeutic use Biology Care and treatment CD4 antigen Clinical outcomes Collaboration Conversion Culture Drug resistance Drug therapy Epidemiology Female Health aspects Highly active antiretroviral therapy Historical account HIV HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Male Medical schools Medicine Microbial drug resistance Mortality Multidrug resistance Multidrug resistant organisms Mycobacterium Patients Physicians Population Remission Induction Retrospective Studies Rural areas South Africa Sputum Sputum - microbiology Sputum - virology Task forces Therapy Time Factors Tuberculosis Tuberculosis, Multidrug-Resistant - complications Tuberculosis, Multidrug-Resistant - drug therapy Young Adult South Africa New York Ann Arbor Michigan United States > US Michigan
ISSN:	1932-6203, 1932-6203
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!